DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
|
|
- Ella Lewis
- 6 years ago
- Views:
Transcription
1 DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016
2 FORWARD LOOKING STATEMENTS This presentation, contains forward- looking statements. These forward- looking statements generally can be identified by the use of words such as believes or belief, anticipates, plans, expects, will, intends, potential, possible, advance and similar expressions. These forward- looking statements include statements about gathering western blot dystrophin data, our plans to submit such data to the FDA and a prompt decision by the FDA; our plans for our clinical development programs and other pipeline plans; the safety and efficacy of eteplirsen and other exon- skipping investigational therapies and the use and/or impact of the data collected; the potential market for our exon skipping product candidates and Sarepta s mission, commitments and business plans and strategies. Forward- looking statements also include those made during the presentation regarding future business developments and actions and the timing of the same. Each forward- looking statement contained in this presentation is subject to risks and uncertainties, including those outside of Sarepta s control, which could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: we may not be able to successfully gather all the data we currently plan to provide to the FDA or may not be able to otherwise comply with FDA requests, to the FDA s satisfaction, with respect to the additional dystrophin data requested by the FDA in a timely manner or at all; even if we provide the FDA with the additional dystrophin data requested, we do not know what the results will show and they could be inconsistent with prior data or result in an FDA finding that the data does not support approval of the eteplirsen NDA, on an expedited timeframe or at all, and the FDA may further delay its approval decision, make additional requests relating to the eteplirsen NDA, provide a complete response letter or otherwise decline to provide marketing approval for eteplirsen; we may not be able to comply with any other FDA requests relating to the eteplirsen NDA submission and the addendums we have submitted to the FDA or with respect to our ongoing or planned clinical trials, in a timely manner or at all; the FDA may further delay its decision on the eteplirsen NDA or may not provide marketing approval for eteplirsen; we may not be able to complete clinical trials required by the FDA for approval of our products or any submissions made in connection with our pipeline of product candidates; the results of our ongoing research and development efforts and clinical trials for our product candidates including eteplirsen and our technologies may not be positive or consistent with prior results or demonstrate a safe treatment benefit or support an NDA filing, positive advisory committee recommendation or marketing approval by the FDA or other regulatory authority; we may not be able to execute on our business plans including meeting our expected or planned regulatory milestones and timelines, clinical development plans and bringing our product candidates to market, including the planned commercialization of eteplirsen, for various reasons, including factors outside of the Company s control, including possible limitations of Company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner or at all, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading Risk Factors in Sarepta s most recent Annual Report on Form 10- K for the year ended December 31, 2015 or Quarterly Report on Form 10- Q for the quarter ended March 31, 2016 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review. Any of the foregoing risks could materially and adversely affect Sarepta's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the Company's filings with the SEC. We caution investors not to place considerable reliance on the forward- looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward- looking statements based on events or circumstances after the date hereof. 2
3 ETEPLIRSEN NEW DRUG APPLICATION (NDA) Current Status Gathering Western blot dystrophin data from the PROMOVI confirmatory study 1 Consists of 13 biopsy samples and will compare baseline values to week 48 values Data will be submitted to FDA over the coming weeks to facilitate a prompt decision on the NDA by the FDA 1 What should you do? Keep in touch and engaged with Duchenne advocacy organizations and other advocates Reach out to Sarepta directly at any time if you have any questions Trial related questions: trialinfo@sarepta.com skipahead@sarepta.com or call DMD- SKIP 1. Sarepta Press Release June 6,
4 OUR CURRENT PLANS SUPPORTING OUR COMMITMENT TO DUCHENNE Sarepta s Phosphorodiamidate Morpholino Oligomer (PMO) Pipeline As per previous slide, NDA for eteplirsen under review by FDA Expand clinical development of SRP and SRP for skipping exons 45 and 53 Planning to have clinical sites in US, Europe, and Canada Continue evaluation of exon- skipping candidates for other amenable exons Other Evaluate next generation exon- skipping therapeutics To continuously evaluate potential combination therapeutic approaches with exon- skipping and other development platforms (e.g., gene therapy) 4
5 AGENDA The Importance of Genetic Testing Exon Skipping Simplified Clinical Development Program Conclusions 5
6 The Importance of Genetic Testing 6
7 DIAGNOSTICS GENETIC TESTING IS ALWAYS NECESSARY 1 Required to determine eligibility for drugs targeted to specific mutations 2 Examples: Exon skipping and nonsense mutation specific therapeutics Enables more thorough understanding of genotype- phenotype 2 Provides additional clinical information to enable proper genetic counseling 1 It is the current standard of diagnosis for Duchenne 1 1. Bushby, K. et al. Lancet Neurol. 2010;9(1): FDA Draft Guidance DMD and Related Dystrophinopathies,
8 GENETIC TESTING FOR DUCHENNE: CURRENT STATUS IN THE UNITED STATES 1 Approximately 40% of boys/men with Duchenne have not received genetic testing Even when genetic testing is performed there remains a significant knowledge gap to interpret the results further to determine amenability to mutation- specific investigational therapies 5,000 % Genotyped by Center Size 4,500 Number of Patients 4,000 3,500 3,000 2,500 2,000 1,500 69% Overall % Genotyped 60% 40% 1, > 100 patients 51% > 50 - < 100 patients 35% < 50 patients Genotyped Not Genotyped 1 Sarepta Therapeutics Data on File 8
9 HOW TO ACCESS GENETIC TESTING Speak to your/your son s doctor about genetic testing for DMD. Was it performed? If Yes Has genetic counseling been offered? Has amenability to mutation- targeted investigational therapeutics been determined? If No Has insurance denied coverage? Was it determined not necessary? PPMD s Decode Duchenne program provides free genetic testing, interpretation, and counseling for people with Duchenne or Becker muscular dystrophy. 1 Example: PPMD resource for physicians to determine exon- skipping amenability 1 duchenneconnect.org. [Internet] [cited 25 June 2016]. Available from: 9
10 Exon Skipping Simplified 10
11 EXON SKIPPING SIMPLIFIED The dystrophin protein acts as a molecular shock absorber, protecting muscle during muscle contraction Boys/men with DMD have little to no dystrophin protein, many with out- of- frame exon deletions, impacting the ability to produce any functional dystrophin The goal of exon skipping is to restore the DMD gene reading frame, allowing for production of a shortened but functional dystrophin protein in patients with out- of- frame deletions 11
12 DYSTROPHIN (DMD) GENE EXON MAP The different shapes represent specific sequences where exons connect to each other The exons need to fit together like a jigsaw puzzle in order to produce dystrophin protein 12
13 DYSTROPHIN (DMD) GENE EXON MAP This is an example of out- of- frame deletions of exons 49 and 50 As you can see, the pieces do not line up and the reading frame is disrupted 13
14 DYSTROPHIN (DMD) GENE EXON MAP PMO Sarepta s PMO technology targets a specific exon to skip, in this case exon 51 14
15 DYSTROPHIN (DMD) GENE EXON MAP PMO Skipping exon 51 allows the reading frame to line up and the potential for production of shortened dystrophin protein 15
16 UNDERSTANDING GENE MUTATIONS This represents DMD gene mutations amenable to skipping exon What is wrong with exon 51? 16
17 Sarepta s Duchenne Clinical Development Program 17
18 DUCHENNE CLINICAL DEVELOPMENT 6 ON- GOING TRIALS, 1 PLANNED Study Name/No. Exon target Length of Study # of Patients (approx.) Key Inclusion Enrollment Status US- 202 Exon weeks year old male Ambulatory Complete Exon weeks ~40 ~20 treated ~20 untreated 4 6 year old male Ambulatory Enrolling (Untreated) Exon weeks ~24 ~24 treated 7 21 year old male Limited to no ambulation Complete (PROMOVI) Exon weeks (plus 48 week extension) ~160 ~80 treated ~ 80 untreated 7 16 year old male Ambulatory Enrolling (Treated and Untreated) Exon 53 Part 1: 12 weeks Part II: 48 weeks 12 (Part I); 48 (Part II) Part I: 8 placebo, 4 treated Part II: 24 treated (12 Part I), 24 untreated 6 15 year old male Ambulatory Complete Exon weeks (plus 108 weeks extension) ~12 ~12 treated (extension phase) 7 21 year old male Limited to no ambulation Complete (ESSENCE) Exon 45 or Exon weeks (plus 96 week extension) ~ year old male Ambulatory Enrolling soon 18
19 EXON 51 SKIPPING (ETEPLIRSEN) CLINICAL DEVELOPMENT Strong consideration of FDA guidance and input from advocates Patients should not be unnecessarily excluded from enrollment in clinical trials due to age or disease stage unless scientifically justified 1 Based on current clinical trials, approximately 135 males in total, amenable to exon 51 skipping, expected to enroll Age 4 6 years (~20 males) Ambulant Age 7 16 years (~92 males) Ambulant Age 7 21 years (~24 males) Limited to no ambulation Study Study US- 202 Study (PROMOVI) Study FDA Draft Guidance DMD and Related Dystrophinopathies,
20 EXON 45 SKIPPING (SRP- 4045) AND EXON 53 SKIPPING (SRP- 4053) CLINICAL DEVELOPMENT Strong Consideration of FDA Guidance and input from advocates Based on current clinical trials, approximately 140 boys/men amenable to exon 45 skipping or 53 skipping expected to enroll Age 6 15 years (~24 males, exon 53) Ambulant Study Age 7 13 years (~ 50 males, exon 45; ~50 males, exon 53) Ambulant Study (ESSENCE) Age 7 21 years (~12 males, exon 45) Limited to no ambulation Study
21 ESSENCE TRIAL DESIGN FOR MUTATIONS AMENABLE TO EXON 45 SKIPPING OR EXON 53 SKIPPING Overview ~ 99 males to enroll 96 week, double- blind, placebo controlled Roll over to open- label for 96 weeks Randomized 2:1 (66 active treatment:33 placebo) Conducted at sites in US, Europe, Canada Inclusion/Exclusion Age 7 13 years Amenable to skipping exon 45 or 53 Average 6MWT (2 consecutive days) meters Stable corticosteroid dose Minimum 24 weeks prior to entry Considerations 2:1 randomization designed to mitigate number of boys on placebo Interim analysis planned when 75% of boys enrolled reach week 48 All boys may roll over to open- label study at end of 96 weeks for 96 weeks For more information go to clinicaltrials.gov/show/nct or contact Sarepta at trialinfo@sarepta.com 21
22 ESSENCE CLINICAL TRIAL (EXON 45 AND 53 SKIPPING) IMPORTANCE/RELEVANCE 1. Confirmatory clinical trial for eteplirsen if granted accelerated approval SRP- 4045and SRP have the same PMO chemistry backbone 2. Pivotal Phase 3 study for SRP and SRP The intent is to file for regulatory approval of both investigational products based on the data from this trial to potentially enable broadest availability for patients with mutations amenable to exon 45 skipping or exon 53 skipping 3. Data to serve as foundation to the advancement of all follow- on exon programs 22
23 ESSENCE TRIAL Q&A (1 OF 2) Why a double- blind, placebo- controlled trial? Following FDA guidance will provide the most efficient pathway to approval To serve as a foundation to the advancement of our follow- on exon skipping products Why was the placebo- control extended from 48 weeks to 96 weeks? A statistically significant divergence (or separation) in 6MWT between boys on eteplirsen versus an external control was not demonstrated at 48 weeks in boys participating in study 201/202 FDA guidance states that efficacy studies of 18 to 24 months duration may substantially increase statistical power while only modestly increasing overall development time We believe that increasing to 96 weeks will increase the likelihood of meeting the primary endpoint leading to broader access to Duchenne populations amenable to these investigational candidates 23
24 ESSENCE TRIAL Q&A (2 OF 2) Why was the age range reduced from age 7 16 years to age 7 13 years? To enroll a very homogenous (similar) population We used the most current understanding of Duchenne to ensure data are interpretable Less predictable disease course in boys > 13 years who walk further than 300 meters on the 6MWT What can the community do? Stay informed with your doctor and other members of the community Sarepta will work closely with investigators, study staff and advocacy organizations to expedite enrollment Contact your doctor or genetic counselor about genetic testing if unsure it has been completed 24
25 CONCLUSIONS Sarepta is committed to continuing our focus on development of potential exon- skipping therapeutics for Duchenne muscular dystrophy Genetic testing is an important first step to determining eligibility for mutation- specific clinical trials Sarepta has ongoing clinical trials actively enrolling in treated and untreated cohorts Phase 3 ESSENCE clinical trial is 1) a confirmatory study for eteplirsen (if granted accelerated approval) 2) aims to demonstrate potential safety and efficacy of SRP- 4045, SRP and 3) may serve as a foundation to the advancement of our future DMD development programs 25
26 WE ARE EXTREMELY GRATEFUL FOR THE CONTINUED SUPPORT OF THE ADVOCACY COMMUNITY, DUCHENNE EXPERTS, TREATERS AND OTHER HEALTHCARE PROFESSIONALS, PARENTS AND FAMILIES, AND MOST OF ALL THE BOYS AND MEN WHO PARTICIPATE IN OUR CLINICAL TRIALS. THANK YOU! 26
-- Study achieved statistical significance on all primary and secondary biological endpoints --
Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Eteplirsen (Exondys 51) for DMD Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy Professional
More informationDuchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Clinical and Commercial Strategy Dr. Leslie Hudson, President and CEO September 10, 2008 Duchenne Muscular Dystrophy (DMD) Defects in the dystrophin gene; no protein expression
More informationAbout Sarepta Therapeutics
Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply -- The partnership will provide commercial supply
More informationPfizer Program in DMD. Beth Belluscio, MD-Ph.D. Pfizer Rare Disease September 9, 2017
Pfizer Program in DMD Beth Belluscio, MD-Ph.D. Pfizer Rare Disease September 9, 2017 Myostatin Inhibitor for the Potential Treatment of Duchenne Muscular Dystrophy Disclaimer This presentation includes
More informationDelivering on the Promise of RNA- Based Therapeu;cs
Delivering on the Promise of RNA- Based Therapeu;cs Parent Project Muscular Dystrophy Webinar June 20, 2011 Forward- Looking Statements This presenta,on includes forward- looking statements, including
More informationSarepta Therapeutics, Inc. (SRPT-NASDAQ)
January 27, 2015 Sarepta Therapeutics, Inc. (SRPT-NASDAQ) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Outperform Date of Last Change 08/12/2013 Current Price (01/26/15) $12.44 Target
More informationExon Skipping. Wendy Erler Patient Advocacy Wave Life Sciences
Exon Skipping Wendy Erler Patient Advocacy Wave Life Sciences Forward Looking Statements This document contains forward-looking statements. All statements other than statements of historical facts contained
More informationNS-065/NCNP-01 Phase 2 dose finding study
NS-065/NCNP-01 Phase 2 dose finding study PPMD Webinar 1 February 22, 2017 Introduction NS Pharma, Inc. (Sponsor) is a wholly-owned, US subsidiary of Nippon Shinyaku Co., Ltd. (Kyoto, Japan) National Center
More information-- Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise --
Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies -- Sarepta
More informationUNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS
GLANCY BINKOW & GOLDBERG LLP Lionel Z. Glancy Michael Goldberg Robert V. Prongay Casey E. Sadler 1925 Century Park East, Suite 2100 Los Angeles, California 90067 Telephone: (310) 201-9150 Facsimile: (310)
More informationEuropean Medicines Agency decision
EMA/643929/2016 European Medicines Agency decision P/0279/2016 of 7 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for Eteplirsen (EMEA- 001722-PIP01-14-M01)
More informationProsensa s continued development of exon-51 skipping with drisapersen after the failure of its phase-iii clinical trial.
A new research report by Dr. Guenter Scheuerbrandt Prosensa s continued development of exon-51 skipping with drisapersen after the failure of its phase-iii clinical trial. In January 2013 you received
More informationEuropean Medicines Agency decision
EMA/866546/2015 European Medicines Agency decision P/0029/2016 of 29 January 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for eteplirsen (EMEA-001722-PIP01-14)
More informationInnovative treatments in neuromuscular disorders
Innovative treatments in neuromuscular disorders Great Ormond Street Hospital for Children NHS Foundation Trust Practical Neurology Study Days 2018 Francesco Muntoni Dubowitz Neuromuscular Centre UCL Institute
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationProsensa Therapeutics R&D in ultra-rare disease
Prosensa Therapeutics R&D in ultra-rare disease European Business Development Conference Dusseldorf, September 24, 2013 Tina C Flatau VP Alliances and Project Management Forward-Looking Statements This
More informationProsensa announces commencement of redosing of drisapersen in North America in patients with Duchenne muscular dystrophy
Prosensa announces commencement of redosing of drisapersen in North America in patients with Duchenne muscular dystrophy Leiden, The Netherlands, Sept. 17, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V.
More informationRegulatory Innovations in Neurological Disorder Therapies, including Spinraza and Exondys 51
Regulatory Innovations in Neurological Disorder Therapies, including Spinraza and Exondys 51 ASENT 19 th Annual Meeting March 15, 2017 Frank Sasinowski, M.S., M.P.H., J.D Director, Hyman, Phelps & McNamara,
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationGene therapies for SMA and DMD
Gene therapies for SMA and DMD Annemieke Aartsma-Rus September 2018 Disclosures Employed by LUMC, which has patents on exon skipping technology, some of which has been licensed to BioMarin and subsequently
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationFDA Regulation of Companion Diagnostics
FDA Regulation of Companion Diagnostics Paul Radensky October 11, 2017 Disclosure + Slideset drawn from Part I of presentation made by Janice Hogan, HoganLovells, October 2016 + Updated where appropriate
More informationDrug Development and Clinical Trials Pat Furlong Parent Project Muscular Dystrophy
Drug Development and Clinical Trials Pat Furlong Parent Project Muscular Dystrophy ParentProjectMD.org -LATE 1990 s Where Are We? - Total NIH funding for MD is $17M -No new drugs in development -Average
More information2018 ASCO Conference Call June 2, 2018
2018 ASCO Conference Call June 2, 2018 1 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the safe harbor provisions
More informationFourth Quarter and Full Year Financial and Operational Results Conference Call March 21, 2018
Fourth Quarter and Full Year 2017 Financial and Operational Results Conference Call March 21, 2018 Copyright Akari Therapeutics, Plc - 2018 Disclaimers Certain statements in this presentation constitute
More informationPTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders. March 2018
PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders March 2018 Mar-18 Page 1 Forward looking statements within the meaning of The Private Securities Litigation
More informationCatabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress -- MoveDMD Trial Data Through One Year of Treatment Reinforce Edasalonexent Potential as Disease-Modifying
More informationTo our fellow shareholders,
BIOCARDIA, INC. To our fellow shareholders, Another year is completed and I remain optimistic about the strength of our therapeutic programs and the progress we are making. There is intense effort being
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationCAP-1002: HOPE Clinical Trials PPMD Annual Conference 2018
CAP-1002: HOPE Clinical Trials PPMD Annual Conference 2018 1 Capricor, Inc. PPMD Annual Conference June 2018 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and
More informationCENTER DIRECTOR DECISIONAL MEMO
CENTER DIRECTOR DECISIONAL MEMO NDA# 206488 Drug Name EXONDYS 51 (eteplirsen) Indication Duchenne Muscular Dystrophy (DMD) Sponsor Sarepta Author Janet Woodcock, M.D. Director, Center for Drug Evaluation
More informationataluren overview A New Approach to Genetic Disorders
ataluren overview A New Approach to Genetic Disorders Ataluren Scientific Background What is ataluren? Ataluren(formerly PTC124) is the first investigational therapy with the potential to enable the formation
More informationAdvancing Mitochondrial Medicine. Günther Metz, SVP Business Development
Advancing Mitochondrial Medicine Günther Metz, SVP Business Development Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to
More informationDuchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry
Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationGEN-003. Positive Phase 2b Clinical Efficacy Results. Immunotherapy Candidate for Genital Herpes. 12-Month Top-line Results
GEN-003 Positive Phase 2b Clinical Efficacy Results Immunotherapy Candidate for Genital Herpes 12-Month Top-line Results Disclaimer This presentation contains forward-looking statements that are within
More informationPTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders JANUARY 2018
PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders JANUARY 2018 Jan-18 Page 1 Forward looking statements within the meaning of The Private Securities Litigation
More informationOpexa Therapeutics, Inc.
Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationNew Drug Application (NDA) Webinar December 6, 2016
New Drug Application (NDA) Webinar December 6, 2016 Introduction Presenter: Jill Jarecki Chief Scientific Officer, Cure SMA New Drug Application Process NDA Not yet an approved therapy: ~90% chance of
More informationStealth BioTherapeutics Mission:
The following is a summary of a live presentation offered through joint collaboration with UMDF, MitoAction and the Foundation for Mitochondrial Medicine to the mitochondrial disease patient and family
More informationSMTC1100: Progressing to Patient Clinical Trials
SMTC1100: Progressing to Patient Clinical Trials Action Duchenne Conference 9 th November 2013 Legal Disclaimer FORWARD LOOKING STATEMENTS This Document contains forward-looking statements. These statements
More informationDear Dr. Janet Woodcock and colleagues at the FDA,
June 25, 2014 Guidance Document Submission Division of Dockets Management (HFA- 305) 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Dr. Janet Woodcock Center for Drug Evaluation and Research Food and
More informationTorreya acted as exclusive financial advisor to Lysogene. About MPS IIIA and LYS-SAF302
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
More information-- Expands Sarepta s portfolio to as many as 14 gene therapy programs --
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
More informationFebruary 15, Re: Docket No. FDA-2017-D-6159: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions
February 15, 2018 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2017-D-6159: Expedited Programs for Regenerative Medicine
More informationUNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS CLASS ACTION COMPLAINT
Case 1:14-cv-10201-MBB Document 1 Filed 01/27/14 Page 1 of 34 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS MARK A. CORBAN, Individually and on Behalf of All Others Similarly Situated,
More informationResults to be Presented at LDN WORLD Symposium in February Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13
Amicus Therapeutics Announces Positive Results from All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease Strong Proof-of-Concept Data for Chaperone
More informationPositive Pompe Phase 1/2 Functional Data in Initial Patients. Conference Call & Webcast. May 15, 2017
Positive Pompe Phase 1/2 Functional Data in Initial Patients Conference Call & Webcast May 15, 2017 Introduction 2 Safe Harbor This presentation contains "forward looking statements" within the meaning
More informationSpeed your time to market with FDA s expedited programs
Regulatory Sciences Expediting drug approval Speed your time to market with FDA s expedited programs The faster way to marketing submission and drug approval for serious conditions and rare diseases In
More informationExpanded Access. to Investigational Drugs & Biologics. for Treatment Use
SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use
More information2016 Summary Financial Results
ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2016 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE -------------------------------------------------------------------------------------------------- GENETIC-AF Phase
More informationDeutsche Bank Health Care Conference
Deutsche Bank Health Care Conference May 8, 2018 NASDAQ: ANIK0 Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including
More informationInformed Consent for Columbia Combined Genetic Panel (CCGP) for Adults Please read the following
Informed Consent for Columbia Combined Genetic Panel (CCGP) for Adults Please read the following form carefully and discuss with your ordering physician/genetic counselor before signing consent. 1. The
More informationMay 9, Meeting Summary. Facilitating Antibacterial Drug Development
May 9, 2012 Meeting Summary Facilitating Antibacterial Drug Development Origins of the Current Public Health Crisis of Antibacterial Resistance Antibacterial drugs play a critical role in the ability to
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationLearning about Clinical Trials
Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the
More informationPhase 1 SMA Type 2 Trial Initiation and Study Design. December 2017
Phase 1 SMA Type 2 Trial Initiation and Study Design December 2017 Disclaimers This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical
More informationCombination Products Coalition ( CPC ); Points to Consider in Drafting FDA s Co-development Guidance and Other Companion Diagnostic Guidances
Companion Diagnostics versus Combination Products 1 Under what circumstances is a companion diagnostic a combination product, and when isn t it a combination product? a) If a companion diagnostic is not
More informationAnnie Kennedy, Parent Project Muscular Dystrophy (PPMD) Testimony FDA PDUFA Stakeholder Meeting White Oak ~ December 17, 2015
Annie Kennedy, Parent Project Muscular Dystrophy (PPMD) Testimony FDA PDUFA Stakeholder Meeting White Oak ~ December 17, 2015 On behalf of Parent Project Muscular Dystrophy (PPMD), we are most grateful
More informationCRISPR/Cas9 and genome editing for genetic neuromuscular disorders
CRISPR/Cas9 and genome editing for genetic neuromuscular disorders Annemieke Aartsma-Rus AFDELING HUMANE GENETICS, LUMC, LEIDEN Disclosures Employed by LUMC, which has patents on exon skipping technology,
More informationMethods for Expediting Innovative Novel Drugs to Market
1 Methods for Expediting Innovative Novel Drugs to Market Presented by: Ada Kung, ( 龔曉嘉博士 ) Ph.D. DABT, MBA akung@expedient-solutions.com www.expedient-solutions.com 2 FDA Guidance for Industry Expedited
More informationFrom Development to Commercial Production: don t contemplate but anticipate
From Development to Commercial Production: don t contemplate but anticipate Automation in the Pharmaceutical Industry Leiden July 8, 2011 Richard Holslag, VP Manufacturing Our Mission To develop innovative,
More information2016 Glaukos Corporation. August 2016
August 2016 DISCLAIMER All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will
More informationCorporate Presentation OCTOBER 2018
Corporate Presentation OCTOBER 2018 This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSwissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia
Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and
More informationINTERNATIONAL SYMPOSIUM ON USHER SYNDROME
(Annamarie Dillon) OK, we are on? Everybody can hear me? Great, first I would like to thank the organizers for the opportunity to come here today to provide you with short updates on our QR-421a program
More informationUS FDA Expedited Programs and Expanded Access
US FDA Expedited Programs and Expanded Access Ke Liu, MD, PhD Chief, Oncology Branch Division of Clinical Evaluation, Pharmacology and Toxicology Office of Tissues and Advanced Therapies Center for Biologics
More informationAttachment B: A Guideline for Writing a Clinical Protocol for CPRN
Attachment B: A Guideline for Writing a Clinical Protocol for CPRN This document provides guidelines for protocol submission. It is only guidance, and the format in which you choose to present the information
More informationCORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016
CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016 Positive remimazolam data in pivotal U.S. Phase III study for procedural sedation during colonoscopy
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationINVESTOR PRESENTATION. June 2018
INVESTOR PRESENTATION June 2018 Safe Harbor Statement This presentation contains forward looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform
More informationFREQUENTLY ASKED QUESTIONS
CLINICAL TRIALS FREQUENTLY ASKED QUESTIONS PARTICIPATING IN A CLINICAL TRIAL What is a clinical trial? Clinical trials are research studies that involve people. Through clinical trials, researchers find
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationDr. Leslie Hudson President and CEO AVI BioPharma
Dr. Leslie Hudson President and CEO AVI BioPharma 1 UBS Investor Conference September 25, 2008 Transitioning an Antisense Pioneer into a Leading RNA-based Drug Discovery and Development Company 2 New Investment
More informationStifel Nicolaus Healthcare Conference. September 2012
Stifel Nicolaus Healthcare Conference September 212 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of
More informationMANUAL: Administrative Policy & Procedure Manual POLICY:
SJMHS Locations: St. Joseph Mercy Ann Arbor, St. Joseph Mercy Chelsea, St. Joseph Mercy Livingston, St. Mary Mercy Livonia MANUAL: Administrative Policy & Procedure Manual POLICY: Expanded access is the
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Safe Harbor Statement This presentation (the Presentation ) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationSarepta Therapeutics (SRPT)
Americas/United States Equity Research Biotechnology Rating OUTPERFORM* [V] Price (22 Sep 14, US$) 20.79 Target price (US$) 36.00¹ 52-week price range 53.81-12.89 Market cap. (US$ m) 850.80 Enterprise
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event
More information2017 Glaukos Corporation. August 2017
August 2017 DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will
More informationINTERMUNE ANNOUNCES TOP-LINE RESULTS OF PHASE 1B TRIAL OF ITMN-191 (R7227) AND PROVIDES PROGRAM UPDATE
Contact: Jim Goff, InterMune, Inc., 415-466-2228, jgoff@intermune.com INTERMUNE ANNOUNCES TOP-LINE RESULTS OF PHASE 1B TRIAL OF ITMN-191 (R7227) AND PROVIDES PROGRAM UPDATE -- Rapid and significant reductions
More informationCelldex Compassionate Use Policy
Celldex Compassionate Use Policy Introduction Currently, none of Celldex s investigational products are available for compassionate use given their early stage of clinical development. The policy outlined
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationCAMBRIDGE, Mass.--(BUSINESS WIRE)--
1 von 6 20.12.2016 17:44 By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes Tue 20 Dec 2016 16:43 - UK Markets are closed Press Release: Sanofi Genzyme
More informationFirst Quarter 2018 Financial Results. May 8, 2018
First Quarter 2018 Financial Results May 8, 2018 Agenda Introduction Sarah Carmody, Senior Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer First Quarter
More informationpsivida Transforms into Commercial Stage Specialty BioPharmaceutical Company ASCRS April 12, 2018 NASDAQ: EYPT
psivida Transforms into Commercial Stage Specialty BioPharmaceutical Company OIS @ ASCRS April 12, 2018 NASDAQ: EYPT Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
More informationThe Importance of Feasibility Studies for Oncology Clinical Trials
The Importance of Feasibility Studies for Oncology Clinical Trials www.ppdi.com Executive Summary The segmenting of the oncology patient population has increased the challenges in designing clinical trials.
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration
More informationThe patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.
Order Form 1. Ordering of the FoundationOne Service The FoundationOne Service comprises the genetic analysis of tumour tissue and the compilation of a comprehensive report on any mutations found in the
More informationBrain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers
FACT SHEET 22 Clinical Trials: Questions and Answers What is a clinical trial? Clinical trials are research studies that answer scientific questions and try to find better ways to prevent, screen for,
More information+61 (0)
ASX Announcement 27 th July 2018 ANP to Present at 14 th Annual Bioshares Biotech Summit Antisense Therapeutics Limited ( the Company or ANP ), is presenting at the 14 th Annual Bioshares Biotech Summit
More informationCORPORATE PRESENTATION January 2019
CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current
More informationConsortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
More informationPluristem Issues Letter to Shareholders
Pluristem Issues Letter to Shareholders HAIFA, Israel, January 30, 2014 -- Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today issued a
More informationRegulatory progress for innovation/international trend on pharmaceutical regulatory convergence Introduction of Horizon Scanning in ICMRA
Regulatory progress for innovation/international trend on pharmaceutical regulatory convergence Introduction of Horizon Scanning in ICMRA 6 th Joint Conference of Japan and Taiwan on Medical Products Regulation
More information